Abstract
Therapeutic dendritic cell (DC) cancer vaccineswork to boost the body's immune system to fight a cancer.Although thistype of immunotherapy often leads to the activation of tumor-specficT cells, clinical responses are fairly low, arguing for the need to improve the design of DC-based vaccines. Recent studies revealed a promising strategy of combining DC vaccines with small interfering RNAs(siRNAs) targeting immunosuppressive signals such as checkpoint receptors. Similarly, incorporating checkpoint siRNA blockers in adoptive T-cell therapy to amplify cytotoxic T lymphocyte responses is now being tested in the clinic. Thedevelopment of the next generation of cancer immunotherapies using siRNA technology will hopefuly benefit patients with various cancer typesincluding those who did not respond to current therapies. This review highlightsthe latest advances in RNA interferencetechnology toimprove the therapeutic efficacy ofDC cancer vaccines and T cell therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
